A Study to Investigate the Safety, Pharmacodynamic and Pharmacokinetic Characteristics of CBP-4888 in Hospitalized Participants With Preterm Preeclampsia and Their Children up to 24 Months

Inclusion Criteria:

• Hospitalized with a hypertensive disorder of pregnancy (preeclampsia) defined byelevated blood pressure after 20 weeks gestation with proteinuria or, in the absenceof proteinuria, with evidence of organ dysfunction (e.g., thrombocytopenia, renalinsufficiency, or impaired liver function), and expected to remain hospitalizedthrough delivery

• The subject has given written consent to participate in the study.

• Pregnant participants aged 18 to 45 years of age

• Gestational age at Day 1 between 26 weeks 0/7 days and 35 weeks 6/7 days

• Deemed clinically stable and suitable for expectant management for at least 72 hourspost CBP-4888 administration

• The woman carries a singleton pregnancy

• Anticipate that hospitalization will continue through delivery

Exclusion Criteria:

• Placenta previa, abruption, accreta, or persistent unexplained vaginal bleeding.

• Fetal growth restriction (<3rd percentile, or <10th percentile with abnormalDoppler) or known major chromosomal/genetic abnormalities.

• Maternal conditions requiring immediate delivery (e.g., severe hypertension,eclampsia, non-reassuring fetal status, pulmonary edema).

• Known active maternal infections considered to potentially affect placentalfunction.

• Significant maternal medical conditions (e.g., HELLP syndrome, advanced kidneydisease, severe cardiac disease, uncontrolled neurological disorder, lupus withnephritis/cerebritis).

• Use of another investigational drug within 30 days prior to study entry.

• Any other condition that, in the investigator's judgment, poses risk to mother orfetus.